Early Metabolic Alterations in Cerebrospinal Fluid Fatty Acid Profiles Linked to Cognitive Decline and All-Cause Dementia
Ayembilla, J. A.; Wadop, Y. N.; Bernal, R.; Ayele, B. A.; Sargurupremraj, M.; Jian, X.; Njamnshi, A. K.; Fongang, B.; Fonteh, A. N.
10.1101/2025.08.25.672205 bioRxivShow abstract
BackgroundWhile All-cause dementia (ACD) may often be characterized by the abnormal deposition of extracellular {beta}-amyloid (A{beta}) in the brain cortex and hyperphosphorylated tau (p-tau) as neurofibrillary tangles intracellularly, there is a need to identify early metabolic changes that may accompany these pathological changes. ObjectiveThis study evaluated the predictive value of fatty acids in cerebrospinal fluid (CSF) fractions in differentiating cognitively unimpaired (CU), mild cognitive impairment (MCI), and ACD participants. MethodsCSF fatty acid profiles were analyzed from CU (n=68), MCI (n=38), and ACD (n=37) individuals aged 77.3 {+/-} 7.7 years, sourced from the Huntington Medical Research Institutes (HMRI). Multivariable binary logistic regression identified the most effective CSF fatty acid biomarkers for distinguishing CU, MCI, and ACD groups. The top-performing CSF fatty acid biomarkers were combined with A{beta}42, tau, and the A{beta}42/tau ratio to evaluate their collective diagnostic performance. The model was adjusted for covariates, including age, sex, smoking status, hypertension, diabetes, and APOE genotype. Receiver operating characteristic (ROC) curves were generated for the top 10 CSF fatty acids ranked by area under the curve (AUC), sensitivity, and specificity, and their significance was assessed using the DeLong test. ResultsThe top 10 fatty acids in CSF fractions demonstrated superior discrimination between CU individuals and those with MCI compared to traditional markers such as A{beta}42, tau, and the A{beta}42/tau ratio. Furthermore, incorporating a panel of these fatty acid biomarkers alongside A{beta}42/tau significantly improved diagnostic accuracy. Age, sex, smoking, hypertension, APOE genotype, and diabetes did not significantly influence the models performance. ConclusionThis study suggests that changes in fatty acid metabolism occur in early ACD pathology. Thus, strategies that regulate fatty acid metabolism may prevent cognitive decline in an older population. HighlightsO_LIThis study revealed that CSF fractions fatty acids have a better discriminatory power for CU from MCI than CSF A{beta}42, tau, and A{beta}42/tau ratio. C_LIO_LIA panel of CSF fraction fatty acids combined with A{beta}42/tau remarkably improved its diagnostic performance for differential diagnosis of CU, MCI, and ACD. C_LIO_LIClinical evaluation of these fatty acids will strengthen the detection of early cognitive impairment. A prospective large cohort multicenter study of the diagnostic utility of CSF fractions fatty acids will provide robust evidence before extensive clinical usage of these fatty acids. C_LI
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status 97%
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 95%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 95%
Similar papers in this journal
- Peripheral inflammation is associated with structural brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer's disease 95%
- Differential responses of primary neuron-secreted MCP-1 and IL-9 to type 2 diabetes and Alzheimer's disease-associated metabolites 94%
- A FinnGen pilot clinical recall study for Alzheimer’s disease 94%
Similar papers in this journal
- Systematic evaluation of multifactorial causal associations for Alzheimer’s disease and an interactive platform based on Mendelian randomization analysis——MRAD 94%
- Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models 92%
- Molecular and cellular similarities in the brain of SARS-CoV-2 and Alzheimer's disease individuals 92%
Similar papers in this journal
- Differences in Plasma Metabolites Related to Alzheimer's Disease, APOE-e4 Status and Ethnicity 94%
- A metabolite-based machine learning approach to diagnose Alzheimer's-type dementia in blood: Results from the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort 93%
- A ketogenic supplement improves white matter energy supply and processing speed in mild cognitive impairment 92%